|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
M.D. Anderson Cancer Center |
| Information provided by: | M.D. Anderson Cancer Center |
| ClinicalTrials.gov Identifier: | NCT00042250 |
Purpose
To determine cell cycle parameters and changes after treatment, the labelling agent is given and a bone marrow aspiration is accomplished before treatment and after treatment for comparison. Participants must be undergoing concurrent therapy for hematologic malignancy.
| Condition | Intervention |
|
Hematologic Malignancies |
Drug: Chemotherapy for hematologic malignancy |
| MedlinePlus related topics: | Cancer |
| ChemIDplus related topics: | Bromodeoxyuridine Idoxuridine |
| Study Type: | Interventional |
| Study Design: | Diagnostic, Non-Randomized, Open Label, Single Group Assignment, Pharmacodynamics Study |
| Official Title: | Cell Cycle Kinetics in Vivo in Patients With Hematologic Malignancies Studied by Iododeoxyuridine and Bromodeoxyuridine Labelling |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Histologic proof of one of:
Participants should be:
Contacts and Locations| United States, Texas | |||||
| M.D. Anderson Cancer Center | |||||
| Houston, Texas, United States, 77030 | |||||
| M.D. Anderson Cancer Center |
| Study Chair: | Michael Andreeff, MD, PhD | U. T. M. D. Anderson Cancer Center |
More Information
M. D. Anderson Cancer Center 
  |
| Study ID Numbers: | DM91-102 |
| First Received: | July 24, 2002 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00042250 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|